Compare THW & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THW | DRTS |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Finance Companies | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 514.7M | 607.1M |
| IPO Year | N/A | N/A |
| Metric | THW | DRTS |
|---|---|---|
| Price | $12.85 | $6.97 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 149.9K | ★ 432.7K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 10.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.76 | $2.30 |
| 52 Week High | $14.89 | $7.89 |
| Indicator | THW | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 61.25 |
| Support Level | $12.67 | $6.23 |
| Resistance Level | $13.03 | $5.14 |
| Average True Range (ATR) | 0.21 | 0.63 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 67.42 | 69.23 |
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.